Neurobooth: A study of motor behavior using digital technologies
The purpose of this study is to create new digital tools to measure speech, movement, and cognition in people with and without neurological diseases. Our goal is to improve the accuracy of diagnosis and the ability to discover effective treatments.
Link to enroll: neurobooth.mgh.harvard.edu
About the Study
Eligible Ataxia Types
All Ataxias
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
04/2022
Estimated Completion Date
N/A – Ongoing
IRB Approval #
2021P000257
Location(s)
Massachusetts General Hospital
15 Parkman Street
Boston, MA
Contact Information
Neurobooth Study Team
neurobooth@mgh.harvard.edu
Phone: 857-238-1520
What does participation in the study entail?
Participants will be guided through a 40-minute assessment that will measure their motor skills, eye movements, speech, and thinking using cameras and a microphone. During this time, participants will complete tasks on a computer and wear sensors on their bodies.
What are the potential benefits for participants?
There are no direct benefits, but your participation will help create new technologies to diagnose and measure neurological diseases and support the development of new treatments.
What are the potential risks for participants?
Potential risks could include loss of confidentiality and anxiety during the assessment.
Is there financial compensation?
Yes. $25 Amazon Gift Card.
Is there travel reimbursement?
No.
Who is eligible?
People who are willing to travel to Boston for the in-person assessment, have a known or possible neurologic condition, have a family history of ataxia, are healthy individuals, and are at least 14 years of age. People with and without symptoms are eligible. We want to develop tools that can detect and measure the earliest signs of ataxia.
View Other Research Opportunities
DRPLA Natural History and Biomarkers Study
This study aims to recruit paediatric and adult DRPLA mutation carriers and healthy controls across different countries. It aims to characterize the natural history of DRPLA in both juvenile- and Read More…
Gene Therapy for the Cardiomyopathy of Friedreich’s Ataxia
The purpose of this study is to test the safety of the study drug, which is an adeno-associated virus serotype rh10 gene transfer vector (AAVrh.10hFXN), and see what effects it Read More…
Using MRI neurofeedback to enhance motor function in ataxia
The purpose of this study is to use a form of brain imaging (real-time functional magnetic resonance imaging, rt-fMRI) combined with neurofeedback, to train people with cerebellar ataxia to improve Read More…
